首页> 外文OA文献 >Practical Tools to Implement Massive Parallel Pyrosequencing of PCR Products in Next Generation Molecular Diagnostics
【2h】

Practical Tools to Implement Massive Parallel Pyrosequencing of PCR Products in Next Generation Molecular Diagnostics

机译:在下一代分子诊断中实现PCR产物大规模平行焦磷酸测序的实用工具

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite improvements in terms of sequence quality and price per basepair, Sanger sequencing remains restricted to screening of individual disease genes. The development of massively parallel sequencing (MPS) technologies heralded an era in which molecular diagnostics for multigenic disorders becomes reality. Here, we outline different PCR amplification based strategies for the screening of a multitude of genes in a patient cohort. We performed a thorough evaluation in terms of set-up, coverage and sequencing variants on the data of 10 GS-FLX experiments (over 200 patients). Crucially, we determined the actual coverage that is required for reliable diagnostic results using MPS, and provide a tool to calculate the number of patients that can be screened in a single run. Finally, we provide an overview of factors contributing to false negative or false positive mutation calls and suggest ways to maximize sensitivity and specificity, both important in a routine setting. By describing practical strategies for screening of multigenic disorders in a multitude of samples and providing answers to questions about minimum required coverage, the number of patients that can be screened in a single run and the factors that may affect sensitivity and specificity we hope to facilitate the implementation of MPS technology in molecular diagnostics. A
机译:尽管在序列质量和每个碱基对的价格方面有所改进,但Sanger测序仍局限于筛选单个疾病基因。大规模并行测序(MPS)技术的发展预示着一个时代,多基因疾病的分子诊断成为现实。在这里,我们概述了基于不同PCR扩增的策略,用于筛选患者队列中的多个基因。我们根据10个GS-FLX实验(超过200名患者)的数据对设置,覆盖范围和测序变异进行了全面评估。至关重要的是,我们确定了使用MPS获得可靠诊断结果所需的实际覆盖率,并提供了一种工具来计算可以在一次运行中筛查的患者数量。最后,我们提供了导致假阴性或假阳性突变调用的因素的概述,并提出了使灵敏度和特异性最大化的方法,这在常规设置中都很重要。通过描述在众多样本中筛查多基因疾病的实用策略并提供有关最低要求覆盖率,可单次筛查的患者人数以及可能影响敏感性和特异性的因素的答案,我们希望有助于在分子诊断中实施MPS技术。一个

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号